As discussed above, HLA-E expression levels are increased in tumor cells as compared to healthy tissues [59,66,97], resulting in the inhibition of cytotoxic NK cells and a subset of CD8 T lymphocytes via its interaction with heterodimer NKG2A/CD94, expressed specifically in those cytotoxic immune populations [98]. The gene discussed is CD8A; the disease is neoplasm.